← The Wire
CABANasdaq
Cabaletta Bio, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1759138
Develops engineered T cell therapies for autoimmune diseases by ablating B cells to reset the immune system
$491M
Market cap
$3.11
Last close
+2.3%
1D
+3.3%
5D
5.5M
Volume
Price · last 39 sessions-18.8%
May 4L $2.80 · H $4.15Jun 29
164
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
Insider Activity
◆ Cluster Buy · 8 insidersIn the 90 days to Jan 21, 2026: 8 insiders bought $296K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 21, 2026 | Nichtberger StevenPresident & CEO | Buy | 45,000 | $2.24 | $101K |
| Jan 21, 2026 | Gavel SteveChief Commercial Officer | Buy | 22,170 | $2.27 | $50K |
| Jan 21, 2026 | Tomasello ShawnDirector | Buy | 22,725 | $2.21 | $50K |
| Jan 21, 2026 | Simon MarkDirector | Buy | 11,061 | $2.28 | $25K |
| Jan 21, 2026 | Binder GwendolynPresident, Science & Tech. | Buy | 11,312 | $2.19 | $25K |
| Jan 21, 2026 | Chang David J.Chief Medical Officer | Buy | 8,800 | $2.26 | $20K |
| Jan 21, 2026 | Gerard MichaelGeneral Counsel | Buy | 6,600 | $2.27 | $15K |
| Jan 21, 2026 | Bollard CatherineDirector | Buy | 4,405 | $2.27 | $10K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance